InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.75
(
-0.18%
)
US TECH 100
19,440.40
(
0.13%
)
Dow Jones
41,950.04
(
-0.61%
)
Brent Oil
73.12
(
-1.94%
)
Bitcoin
63,452.50
(
-1.28%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Wopsal101

Send PM Follow Ignore
Followers 4
Posts 316
Boards Moderated 0
Alias Born 02/09/2013

Wopsal101

Re: homeslice10 post# 78036

Saturday, 12/20/2014 6:39:42 PM

Saturday, December 20, 2014 6:39:42 PM

Post# of 92948
You are forgetting about the Orphan Designation. This gives Ocata some flexibility as far as government grants, premium pricing, and market protection. Orphan designation is a big deal. Also Stargardts is widely accepted as the juvenile form of AMD so the results will be accepted in the AMD trial. Hopefully physicians will be able to use the cells off label for AMD earlier than they would otherwise.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up